The COPD Assessment Test: What Do We Know So Far?

A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages


      The COPD Assessment Test (CAT) was developed as a simple instrument to assess health status in patients with COPD. This study aimed to systematically review the determinants of the CAT score, its ability to predict clinical outcomes, and the agreement between CAT (≥ 10) and the modified Medical Research Council scale (mMRC ≥ 2) to categorize patients into the new Global Initiative for Chronic Obstructive Lung Disease classification system.


      From January 1, 2009, to June 30, 2015, databases were searched for studies using CAT in adults with COPD and in general populations aiming to detect COPD. Two investigators independently screened, selected, and extracted data by using a standardized form. Where appropriate, the results were combined in a random effects meta-analysis.


      Of 453 studies, 17 were included, and eight were used in the meta-analysis. The models to predict the CAT score were able to explain < 50% of its variance. CAT scores can indicate risk of exacerbation, depression, acute deterioration in health status, and mortality. All studies found a different proportion of patients in each Global Initiative for Chronic Obstructive Lung Disease category using CAT ≥ 10 or mMRC ≥ 2. On average, the distribution was 13% different according to the instrument used. The κ agreement between CAT and mMRC ranged from 0.13 to 0.77.


      CAT may be used as a complementary tool in a patient's clinical assessment to predict COPD exacerbation, health status deterioration, depression, and mortality. The interpretation of this meta-analysis does not support the use of the recommended cutoff points of ≥10 for CAT and ≥2 for mMRC as equivalents for the purpose of assessing patient symptoms.

      Key Words


      AUC ( area under the receiver-operating characteristic curve), CAT ( COPD Assessment Test), GOLD ( Global Initiative for Chronic Obstructive Lung Disease), mMRC ( modified Medical Research Council scale)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Menezes A.M.
        • Perez-Padilla R.
        • Jardim J.R.
        • et al.
        Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.
        Lancet. 2005; 366: 1875-1881
        • Vestbo J.
        • Hurd S.S.
        • Agusti A.G.
        • et al.
        Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
        Am J Respir Crit Care Med. 2013; 187: 347-365
        • Reardon J.Z.
        • Lareau S.C.
        • ZuWallack R.
        Functional status and quality of life in chronic obstructive pulmonary disease.
        Am J Med. 2006; 119: 32-37
      1. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Accessed July 15, 2015.

        • Jones P.W.
        • Quirk F.H.
        • Baveystock C.M.
        • Littlejohns P.
        A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.
        Am Rev Respir Dis. 1992; 145: 1321-1327
        • Weldam S.W.
        • Schuurmans M.J.
        • Liu R.
        • Lammers J.W.
        Evaluation of quality of life instruments for use in COPD care and research: a systematic review.
        Int J Nurs Stud. 2013; 50: 688-707
        • Guyatt G.H.
        • Berman L.B.
        • Townsend M.
        • Pugsley S.O.
        • Chambers L.W.
        A measure of quality of life for clinical trials in chronic lung disease.
        Thorax. 1987; 42: 773-778
        • Ringbaek T.
        • Martinez G.
        • Lange P.
        A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation.
        COPD. 2012; 9: 12-15
        • Jones P.
        • Harding G.
        • Wiklund I.
        • Berry P.
        • Leidy N.
        Improving the process and outcome of care in COPD: development of a standardised assessment tool.
        Prim Care Respir J. 2009; 18: 208-215
        • Jones P.W.
        • Harding G.
        • Berry P.
        • Wiklund I.
        • Chen W.H.
        • Kline Leidy N.
        Development and first validation of the COPD Assessment Test.
        Eur Respir J. 2009; 34: 648-654
        • Jones P.W.
        Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group.
        Eur Respir J. 1994; 7: 55-62
        • Gupta N.
        • Pinto L.M.
        • Morogan A.
        • Bourbeau J.
        The COPD assessment test: a systematic review.
        Eur Respir J. 2014; 44: 873-884
        • Kon S.S.
        • Canavan J.L.
        • Jones S.E.
        • et al.
        Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.
        Lancet Respir Med. 2014; 2: 195-203
        • Jones P.W.
        COPD assessment test—rationale, development, validation and performance.
        COPD. 2013; 10: 269-271
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • The PRISMA Group (2009)
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Whiting P.F.
        • Rutjes A.W.
        • Westwood M.E.
        • et al.
        QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.
        Ann Intern Med. 2011; 155: 529-536
        • Kelly J.L.
        • Bamsey O.
        • Smith C.
        • et al.
        Health status assessment in routine clinical practice: the Chronic Obstructive Pulmonary Disease Assessment Test score in outpatients.
        Respiration. 2012; 84: 193-199
        • Papaioannou M.
        • Pitsiou G.
        • Manika K.
        • et al.
        COPD Assessment Test: a simple tool to evaluate disease severity and response to treatment.
        COPD. 2014; 11: 489-495
        • Lee Y.S.
        • Park S.
        • Oh Y.M.
        • et al.
        Chronic obstructive pulmonary disease assessment test can predict depression: a prospective multi-center study.
        J Korean Med Sci. 2013; 28: 1048-1054
        • Lee S.D.
        • Huang M.S.
        • Kang J.
        • et al.
        The COPD Assessment Test (CAT) assists prediction of COPD exacerbations in high-risk patients.
        Respir Med. 2014; 108: 600-608
        • Pothirat C.
        • Chaiwong W.
        • Limsukon A.
        • et al.
        Detection of acute deterioration in health status visit among COPD patients by monitoring COPD assessment test score.
        Int J Chron Obstruct Pulmon Dis. 2015; 10: 277-282
        • Raghavan N.
        • Lam Y.M.
        • Webb K.A.
        • et al.
        Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample.
        COPD. 2012; 9: 175-183
        • Casanova C.
        • Marin J.M.
        • Martinez-Gonzalez C.
        • et al.
        Differential effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD.
        Chest. 2015; 148: 159-168
        • Han M.K.
        • Muellerova H.
        • Curran-Everett D.
        • et al.
        GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.
        Lancet Respir Med. 2013; 1: 43-50
        • Jones P.W.
        • Adamek L.
        • Nadeau G.
        • Banik N.
        Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification.
        Eur Respir J. 2013; 42: 647-654
        • Kim S.
        • Oh J.
        • Kim Y.I.
        • et al.
        Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses.
        BMC Pulm Med. 2013; 13: 35
        • Pillai A.P.
        • Turner A.M.
        • Stockley R.A.
        Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in alpha1-antitrypsin deficiency.
        Chest. 2013; 144: 1152-1162
        • Casanova C.
        • Marin J.M.
        • Martinez-Gonzalez C.
        • et al.
        New GOLD classification: longitudinal data on group assignment.
        Respir Res. 2014; 15: 3
        • Jones P.W.
        • Nadeau G.
        • Small M.
        • Adamek L.
        Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations.
        Respir Med. 2014; 108: 129-135
        • Price D.B.
        • Baker C.L.
        • Zou K.H.
        • Higgins V.S.
        • Bailey J.T.
        • Pike J.S.
        Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification.
        Int J Chron Obstruct Pulmon Dis. 2014; 9: 551-561
        • Rieger-Reyes C.
        • Garcia-Tirado F.J.
        • Rubio-Galan F.J.
        • Marin-Trigo J.M.
        Classification of chronic obstructive pulmonary disease severity according to the new Global Initiative for Chronic Obstructive Lung Disease 2011 guidelines: COPD assessment test versus modified Medical Research Council scale.
        Arch Bronconeumol. 2014; 50: 129-134
        • Zogg S.
        • Durr S.
        • Miedinger D.
        • Steveling E.H.
        • Maier S.
        • Leuppi J.D.
        Differences in classification of COPD patients into risk groups A-D: a cross-sectional study.
        BMC Res Notes. 2014; 7: 562
        • Han J.
        • Dai L.
        • Zhong N.
        • Young D.
        Breathlessness or health status in chronic obstructive pulmonary disease: the impact of different definitions.
        COPD. 2015; 12: 115-125